NCT05658289 Latarjet vs Anatomic Glenoid Reconstruction
| NCT ID | NCT05658289 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nova Scotia Health Authority |
| Condition | Shoulder Dislocation |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2023-04-24 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2023-04-24 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Anterior shoulder dislocations occur when the humeral head translates anterior to the glenoid cause pain, stiffness, and glenoid bone loss. If left untreated, the risk of recurrence can be up to or greater than 90%. The only surgically modifiable factor to reduce the risk of recurrence is the glenoid bone loss (GBL), where surgeons have the ability to recreate the shape of the glenoid and reduce the risk of recurrent shoulder dislocations. Established boney procedures for shoulder instability include the Latarjet and free bone block procedures, such as the Anatomic Glenoid Reconstruction (AGR). The Latarjet is well known for its lower rate of recurrent instability, but raises concerns due to under-appreciated complications rates. The AGR is a newer surgical approach that has garnered attention for its low rate of recurrent instability and complication profile. Both treatments can reduce pain, increase function following surgery and reduce the risk of recurrent instability. However, these two established approaches have yet to be directly compared and studied on a larger scale. The purpose of this randomized control trial is to compare clinical and radiographic outcomes pre- and post-operatively between the Latarjet to the AGR.
Eligibility Criteria
Inclusion Criteria: * Patients with one or more instances of anterior shoulder dislocation; pre-operative CT scan illustrating \>20% bone loss. Exclusion Criteria: * posterior shoulder instability; multidirectional shoulder instability; massive rotator cuff teats (MRI proven); history of substance abuse, patients unable to provide informed consent, patients refusing randomization.
Contact & Investigator
Ivan Wong, MD
PRINCIPAL INVESTIGATOR
Nova Scotia Health Authority, Orthopaedic Surgeon
Frequently Asked Questions
Who can join the NCT05658289 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 40 Years, studying Shoulder Dislocation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05658289 currently recruiting?
Yes, NCT05658289 is actively recruiting participants. Contact the research team at research@drivanwong.com for enrollment information.
Where is the NCT05658289 trial being conducted?
This trial is being conducted at Halifax, Canada.
Who is sponsoring the NCT05658289 clinical trial?
NCT05658289 is sponsored by Nova Scotia Health Authority. The principal investigator is Ivan Wong, MD at Nova Scotia Health Authority, Orthopaedic Surgeon. The trial plans to enroll 68 participants.